Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?
This trial is active, not recruiting.
|Conditions||growth hormone treatment, glaucoma|
|Treatment||measuring intraoccular pressure|
|Sponsor||Assaf-Harofeh Medical Center|
|Start date||February 2009|
|End date||October 2010|
|Trial size||100 participants|
|Trial identifier||NCT00867971, 162/08|
Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described. Several years ago, a case report was published concerning a child that was treated with RGH and developed acute glaucoma. To date no study has evaluated the connection.
Intraoccular pressure in children treated with RGH
time frame: 2 years
Male or female participants from 6 years up to 18 years old.
Inclusion Criteria: - Age 6-18 years - treatment with recombinant growth hormone Exclusion Criteria: - Underlying Chronic diseases - Family history of eye diseases - elevated occular pressure prior to starting treatment
Call for more information